KR20240021920A - 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제 - Google Patents

수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제 Download PDF

Info

Publication number
KR20240021920A
KR20240021920A KR1020247001376A KR20247001376A KR20240021920A KR 20240021920 A KR20240021920 A KR 20240021920A KR 1020247001376 A KR1020247001376 A KR 1020247001376A KR 20247001376 A KR20247001376 A KR 20247001376A KR 20240021920 A KR20240021920 A KR 20240021920A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
oxybutynin
administered
nri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247001376A
Other languages
English (en)
Korean (ko)
Inventor
루이지 타란토-몬테무로
로날드 파카스
데이비드 피. 화이트
로렌스 쥐. 밀러
Original Assignee
애프니메드, 인코포레이티드 (델라웨어)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애프니메드, 인코포레이티드 (델라웨어) filed Critical 애프니메드, 인코포레이티드 (델라웨어)
Publication of KR20240021920A publication Critical patent/KR20240021920A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020247001376A 2021-06-17 2022-06-17 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제 Pending KR20240021920A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163211673P 2021-06-17 2021-06-17
US63/211,673 2021-06-17
US202263319035P 2022-03-11 2022-03-11
US63/319,035 2022-03-11
PCT/US2022/033987 WO2022266440A1 (en) 2021-06-17 2022-06-17 Norepinephrine reuptake inhibitors for treating sleep apnea

Publications (1)

Publication Number Publication Date
KR20240021920A true KR20240021920A (ko) 2024-02-19

Family

ID=82608262

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001376A Pending KR20240021920A (ko) 2021-06-17 2022-06-17 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제

Country Status (10)

Country Link
US (1) US20240277719A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355333A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024523876A (cg-RX-API-DMAC7.html)
KR (1) KR20240021920A (cg-RX-API-DMAC7.html)
AU (1) AU2022294086A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023026158A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221848A1 (cg-RX-API-DMAC7.html)
IL (1) IL309251A (cg-RX-API-DMAC7.html)
MX (1) MX2023014709A (cg-RX-API-DMAC7.html)
WO (1) WO2022266440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106773A1 (en) * 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CN119185558A (zh) * 2017-04-28 2024-12-27 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
CN111670050A (zh) * 2018-01-30 2020-09-15 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
CA3117766A1 (en) * 2018-10-31 2020-05-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
ES3049086T3 (en) * 2019-02-08 2025-12-12 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
US20240075035A1 (en) * 2021-01-14 2024-03-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
EP4355333A1 (en) 2024-04-24
MX2023014709A (es) 2024-01-15
US20240277719A1 (en) 2024-08-22
WO2022266440A1 (en) 2022-12-22
CA3221848A1 (en) 2022-12-22
BR112023026158A2 (pt) 2024-03-05
JP2024523876A (ja) 2024-07-02
IL309251A (en) 2024-02-01
AU2022294086A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
JP7422666B2 (ja) 睡眠時無呼吸を治療するための方法および組成物
US20240075035A1 (en) Methods and compositions for treating sleep apnea
US20240277719A1 (en) Norepinephrine reuptake inhibitors for treating sleep apnea
US20230135373A1 (en) Methods and compositions for treating sleep apnea
US20240358709A1 (en) Methods and compositions for treating sleep apnea
US20240173337A1 (en) Methods and compositions for treating sleep apnea
US20250009720A1 (en) Methods and compositions for treating sleep apnea
CN117615764A (zh) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂
US20250302814A1 (en) Methods and compositions for treating sleep apnea
JP2025527796A (ja) 睡眠時無呼吸を治療するための方法及び組成物
US20240139200A1 (en) Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
WO2024220343A1 (en) Combination of a norepinephrine reuptake inhibitor and a melatonin receptor agonist for use in treating sleep apnea
US20250241933A1 (en) Methods of treating sleep apnea with a combination of a cannabinoid and a carbonic anhydrase inhibitor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250613

Comment text: Request for Examination of Application